Investigational drug · Phase 3
Remimazolam Tosilate
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Sedation in the ICU, Operative Sedation of Pediatric, Operative Sedation of Adolescent Patients.
Phase 3Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
28
Any phase or sponsor naming "Remimazolam Tosilate"
First trial start
2023
Jun 27, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Remimazolam Tosilate", any sponsor or status.
Conditions studied
As listed on its trial records.
- Sedation in the ICU
- Operative Sedation of Pediatric
- Operative Sedation of Adolescent Patients
Approved drugs for the same conditions: Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "Remimazolam Tosilate" as an intervention, largest first.
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05254366 · 2,022 participants · Start Jan 30, 2022 · Primary completion Feb 8, 2023
Drug: Remimazolam Tosilate for Injection · For: Gastroscopic and Colonoscopic Sedation
Sites: Chizhou, China; Shantou, China; Shenzhen, China · 19 sites in all
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05549791 · 1,285 participants · Start Aug 18, 2022 · Primary completion Jun 21, 2024
Drug: Remimazolam Tosilate for Injection · For: General Anesthesia and Bronchoscopy Sedation
Sites: Changsha, China
- Impact of Remimazolam on Prognosis After Bladder Cancer SurgeryPivotal-lookingRecruiting
Peking University First HospitalAcademic, hospital or other
NCT04532606 · 1,128 participants (planned) · Start Feb 5, 2021 · Primary completion Oct 2025
Drug: Remimazolam; Propofol · For: Benzodiazepines; Bladder Cancer; Delirium and 2 more
Sites: Beijing, China; Beijin, China; Guiyang, China · 6 sites in all
- Study on the Safety and Effectiveness of Remimazolam Tosilate for Injection for Short-term Elective Surgery in AdultsPivotal-lookingCompleted
Tongji HospitalAcademic, hospital or other
NCT04908553 · 650 participants · Start Jul 1, 2021 · Primary completion Mar 30, 2025
Drug: Remimazolam Tosilate for Injection 0.1mg/kg; Remimazolam Tosilate for Injection 0.15mg/kg and 1 more · For: Hypotension During Surgery
Sites: Wuhan, China
- Study of Remimazolam Tosilate in Patients Undergoing ColonoscopyPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT03779061 · 388 participants · Start Jun 28, 2018 · Primary completion Sep 20, 2018
Drug: Remimazolam Tosilate; Propofol · For: Sedation
Sites: Beijing, China
- Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI EndoscopyPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT03425474 · 378 participants · Start Sep 1, 2017 · Primary completion Nov 10, 2017
Drug: Remimazolam Tosilate; Propofol · For: Sedation
Sites: Beijing, China
- Comparison Between Remimazolam Tosilate and Midazolam in Elderly Patients Undergoing Gastrointestinal EndoscopyPivotal-lookingCompleted
Peking University People's HospitalAcademic, hospital or other
NCT04656964 · 353 participants · Start Apr 1, 2021 · Primary completion Dec 31, 2022
Drug: remimazolam tosilate group; Midazolam group · For: Elderly Patients; Gastrointestinal Endoscopy; Midazolam and 1 more
Sites: Beijing, China
- A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective SurgeryPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT03921775 · 330 participants · Start May 13, 2019 · Primary completion Dec 30, 2019
Drug: Remimazolam Tosilate; Propofol · For: Anesthesia for Elective Surgery Patients
Sites: Beijing, China
- A Clinical Study of Remimazolam Tosilate in Patients Undergoing BronchoscopyPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04400201 · 330 participants · Start Jun 15, 2020 · Primary completion Oct 28, 2020
Drug: Remimazolam Tosilate; Propofol · For: Sedation
Sites: Beijing, China
- Remimazolam vs Propofol for Long-Term Sedation in Mechanically Ventilated ICU PatientsPivotal-lookingNot yet recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT07880548 · 274 participants (planned) · Start Oct 20, 2026 · Primary completion Jul 31, 2028
Drug: Remimazolam group; Propofol group · For: Long-term Sedation for Mechanical Ventilation; Critically Ill Intensive Care Unit Patients
Sites: Dongguan, China; Guangzhou, China; Shenzhen, China · 21 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Short-term postoperative neurocognitive safety and recovery profiles of remimazolam tosilate combined with flumazenil vs. propofol in cirrhotic patients undergoing endoscopic variceal treatment: a randomized controlled trial.
Chen Y, Du X, Shi F, et al. · Front Med (Lausanne) 2026
- Remimazolam tosilate combined with remifentanil hydrochloride alleviates dental phobia in patients undergoing tooth extraction surgeries.
Cao C, Yan H, Cheng C, et al. · Odontology 2026
- Age-Stratified ED9 5 of Remimazolam Tosilate for Moderate Sedation in Pediatric Patients: A Biased Coin Design Study.
Zhu B, Meng W, Pan K, et al. · Drug Des Devel Ther 2026
- Application value and safety advantages of remimazolam tosilate in sedation for emergency rescue endotracheal intubation.
Yang D, Chen J, Lin X, et al. · Am J Transl Res 2026
- Dose Recommendation of Remimazolam Tosilate for General Anesthesia in Children and Adolescents: Synergistic Combination of PopPK and PBPK Approaches.
Liang QY, Hu HH, Djebli N, et al. · Pharmaceutics 2026
- Adverse event prediction in propofol-remimazolam tosilate anesthesia.
Zhai M, Sun F, Liang S · Front Med (Lausanne) 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.